Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience

American Heart Journal

Volumn 166, Issue 3, 2013, Pages 597-603

  Mampuya, Warner M ^a   Frid, David ^b   Rocco, Michael ^b   Huang, Julie ^b   Brennan, Danielle M ^b   Hazen, Stanley L ^b   Cho, Leslie ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOSITIS; NEUROLOGIC DISEASE; PANCREATITIS; PRIORITY JOURNAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; WEAKNESS;

ADULT; AGED; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84883777708     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.06.004     Document Type: Article

References (29)

1. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
2. A.Y. Cheng, and L.A. Leiter Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Curr Opin Cardiol 21 2006 400 404
3. M.H. Davidson, and J.G. Robinson Safety of aggressive lipid management J Am Coll Cardiol 49 2007 1753 1762
4. A. Kashani, C.O. Phillips, and J.M. Foody Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
5. Y.H. Gomez Sandoval, M.V. Braganza, and S.S. Daskalopoulou Statin discontinuation in high-risk patients: a systematic review of the evidence Curr Pharm Des 17 2011 3669 3689
6. G. Fernandez, E.S. Spatz, and C. Jablecki Statin myopathy: a common dilemma not reflected in clinical trials Cleve Clin J Med 78 2011 393 403
7. E. Bruckert, G. Hayem, and S. Dejager Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
8. C. Buettner, R.B. Davis, and S.G. Leveille Prevalence of musculoskeletal pain and statin use J Gen Intern Med 23 2008 1182 1186
9. P. Maningat, and J.L. Breslow Needed: pragmatic clinical trials for statin-intolerant patients N Engl J Med 365 2011 2250
10. H. Zhang, J. Plutzky, and S. Skentzos Discontinuation of statins in routine care settings. A cohort study Ann Intern Med 158 2013 526 534
11. J.A. Farmer, and G. Torre-Amione Comparative tolerability of the HMG-CoA reductase inhibitors Drug Saf 23 2000 197 213
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
13. J.M. Backes, P.M. Moriarty, and J.F. Ruisinger Effects of once weekly rosuvastatin among patients with a prior statin intolerance Am J Cardiol 100 2007 554 555
14. J.M. Backes, C.V. Venero, and C.A. Gibson Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance Ann Pharmacother 42 2008 341 346
15. M. Gadarla, A.K. Kearns, and P.D. Thompson Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins Am J Cardiol 101 2008 1747 1748
16. C.J. Glueck, D. Aregawi, and M. Agloria Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies Clin Ther 28 2006 933 942
17. ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 2002 567 572
18. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
19. K. Tziomalos, V.G. Athyros, and D.P. Mikhailidis Statin discontinuation: an underestimated risk? [Editorial] Curr Med Res Opin 24 2008 3059 3062
20. B.D. Mackie, S. Satija, and C. Nell Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy Am J Cardiol 99 2007 291
21. J.F. Ruisinger, J.M. Backes, and C.A. Gibson Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance Am J Cardiol 103 2009 393 394
22. F.I. Marcus, A.J. Baumgarten, and W.L. Fritz Alternate-day dosing with statins Am J Med 126 2 Feb. 2013 99 104
23. S.P. Kennedy, G.P. Barnas, and M.J. Schmidt Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance J Clin Lipidol 5 2011 308 315
24. M. Jafari, R. Ebrahimi, and M. Ahmadi-Kashani Efficacy of alternate-day dosing versus daily dosing of atorvastatin J Cardiovasc Pharmacol Ther 8 2003 123 126
25. M. Kayikcioglu, F. Ozerkan, and I. Soydan Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia Am J Cardiol 83 1999 1135 1137
26. V.G. Athyros, K. Tziomalos, and A.I. Kakafika Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients Am J Cardiol 101 2008 483 485
27. M.S. Matalka, M.C. Ravnan, and P.C. Deedwania Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS) Am Heart J 144 2002 674 677
28. J.P. Rindone, D. Hiller, and G. Arriola A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia Pharmacotherapy 18 1998 836 839
29. J.C. Ferrer-Garcia, J. Perez-Silvestre, and I. Martinez-Mir Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia Acta Diabetol 43 2006 75 78